Demographic, renal, and hematologic findings at presentation in patients with LN and aHUS
| Patient . | Age, y/sex . | Renal biopsy . | Status pre-eculizumab . | Cr on admission, mg/dL . | LDH, U/L . | Platelets on admission, ×109/L . | C3, mg/dL . | C4, mg/dL . | ADAMTS13, % activity . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39/F | FSGLN, membranous LN, antibody-mediated rejection, TMA | ESRD due to LN | 3.64 | 2013 | 91 | Not obtained | Not obtained | Not obtained |
| Renal allograft rejection | |||||||||
| 2 | 25/F | Diffuse proliferative glomerulonephritis class IV, TMA | ESRD due to LN | 1.30 | 368 | 48 | 13 | 3 | 67 |
| 3 | 22/F | Diffuse proliferative LN class IV, TMA | ESRD due to LN | 3.87 | 461 | 82 | 14 | <2 | 98 |
| 4 | 37/F | Not obtained | ESRD due to LN | 5.58 | 325 | 57 | 80 | 26 | Not obtained |
| 5 | 31/F | LN class III, TMA | ESRD due to LN fungemia | 2.46 | 672 | 90 | 21 | 2 | 89 |
| 6 | 42/F | Chronic interstitial nephritis and diffuse mesangial hypercellularity, TMA | LN never on dialysis APLS | 2.00 | 247 | 78 | 96 | 11 | 123 |
| 7 | 59/F | Not obtained | LN never on dialysis | 1.98 | 456 | 8 | 54 | 8 | 99 |
| 8 | 22/F | Membranous lupus glomerulonephritis, mixed class III, V, clinical TMA | LN never on dialysis; nephrotic syndrome | 3.17 | 254 | 160 | 18 | <2 | Not obtained |
| 9 | 31/M | Diffuse LN class IV-G, TMA | ESRD due to LN | 3.64 | 335 | 49 | Not obtained | Not obtained | 89 |
| 10 | 34/F | Interstitial fibrosis, TMA | ESRD LN myocarditis APLS | 2.86 | 806 | 60 | 119 | 21 | 151 |
| 11 | 57/M | Not obtained | ESRD LN APLS | 4.13 | 1955 | 28 | 128 | 28 | Not obtained |
| Patient . | Age, y/sex . | Renal biopsy . | Status pre-eculizumab . | Cr on admission, mg/dL . | LDH, U/L . | Platelets on admission, ×109/L . | C3, mg/dL . | C4, mg/dL . | ADAMTS13, % activity . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39/F | FSGLN, membranous LN, antibody-mediated rejection, TMA | ESRD due to LN | 3.64 | 2013 | 91 | Not obtained | Not obtained | Not obtained |
| Renal allograft rejection | |||||||||
| 2 | 25/F | Diffuse proliferative glomerulonephritis class IV, TMA | ESRD due to LN | 1.30 | 368 | 48 | 13 | 3 | 67 |
| 3 | 22/F | Diffuse proliferative LN class IV, TMA | ESRD due to LN | 3.87 | 461 | 82 | 14 | <2 | 98 |
| 4 | 37/F | Not obtained | ESRD due to LN | 5.58 | 325 | 57 | 80 | 26 | Not obtained |
| 5 | 31/F | LN class III, TMA | ESRD due to LN fungemia | 2.46 | 672 | 90 | 21 | 2 | 89 |
| 6 | 42/F | Chronic interstitial nephritis and diffuse mesangial hypercellularity, TMA | LN never on dialysis APLS | 2.00 | 247 | 78 | 96 | 11 | 123 |
| 7 | 59/F | Not obtained | LN never on dialysis | 1.98 | 456 | 8 | 54 | 8 | 99 |
| 8 | 22/F | Membranous lupus glomerulonephritis, mixed class III, V, clinical TMA | LN never on dialysis; nephrotic syndrome | 3.17 | 254 | 160 | 18 | <2 | Not obtained |
| 9 | 31/M | Diffuse LN class IV-G, TMA | ESRD due to LN | 3.64 | 335 | 49 | Not obtained | Not obtained | 89 |
| 10 | 34/F | Interstitial fibrosis, TMA | ESRD LN myocarditis APLS | 2.86 | 806 | 60 | 119 | 21 | 151 |
| 11 | 57/M | Not obtained | ESRD LN APLS | 4.13 | 1955 | 28 | 128 | 28 | Not obtained |
All patients met criteria for systemic lupus erythematosus.
APLS, antiphospholipid antibody syndrome; C3, complement 3; C4, complement 4; Cr, creatinine; ESRD, end-stage renal disease; F, female; FSGLN, focal segmental glomerulonephritis; M, male.